David Back mostly deals with Pharmacology, Pharmacokinetics, Internal medicine, Ritonavir and Endocrinology. His specific area of interest is Pharmacology, where David Back studies Drug interaction. His Pharmacokinetics research is multidisciplinary, relying on both Oral administration, CYP3A4, Chemotherapy and Zidovudine.
David Back combines subjects such as Antibiotics, Rifampicin, Gastroenterology, Anticonvulsant and Single-nucleotide polymorphism with his study of Internal medicine. His studies in Ritonavir integrate themes in fields like Protease inhibitor, Lopinavir, HIV Protease Inhibitor, Saquinavir and Indinavir. His biological study deals with issues like Bioavailability, which deal with fields such as Volume of distribution.
David Back mainly focuses on Pharmacology, Pharmacokinetics, Internal medicine, Endocrinology and Ritonavir. David Back works mostly in the field of Pharmacology, limiting it down to topics relating to Zidovudine and, in certain cases, Lamivudine, as a part of the same area of interest. His work deals with themes such as Oral administration, Area under the curve, Reverse-transcriptase inhibitor and Virology, which intersect with Pharmacokinetics.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Bioavailability. His studies deal with areas such as Microsome and Norethisterone as well as Endocrinology. His Ritonavir research also works with subjects such as
David Back spends much of his time researching Pharmacology, Pharmacokinetics, Drug, Efavirenz and Ritonavir. His Pharmacology research focuses on Raltegravir and how it connects with Raltegravir Potassium. Pharmacokinetics is a subfield of Internal medicine that David Back investigates.
In Drug, David Back works on issues like Intensive care medicine, which are connected to Disease and Coronavirus disease 2019. His work is dedicated to discovering how Efavirenz, Nevirapine are connected with Obstetrics and other disciplines. As a part of the same scientific study, he usually deals with the Ritonavir, concentrating on Lopinavir and frequently concerns with Lopinavir/ritonavir.
Pharmacology, Pharmacokinetics, Efavirenz, Nevirapine and Lopinavir are his primary areas of study. He combines subjects such as Internal medicine, Atazanavir and Ritonavir with his study of Pharmacology. His Pharmacokinetics research incorporates elements of Pre-exposure prophylaxis, Confidence interval, Dosing and Emtricitabine.
His Efavirenz study combines topics from a wide range of disciplines, such as Half-life, Virology, Pharmacogenetics, Cmax and Breast milk. His Nevirapine research focuses on Rilpivirine and how it relates to IC50. He interconnects Organic anion transporter 1, SLCO1B1, Protease and Genotype in the investigation of issues within Lopinavir.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Jacques Fellay;Catia Marzolini;Emma R. Meaden;David J. Back.
The Lancet (2002)
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
Victoria A. Eagling;John F. Tjia;David J. Back.
British Journal of Clinical Pharmacology (1998)
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
V. A. Eagling;D. J. Back;M. G. Barry.
British Journal of Clinical Pharmacology (2003)
Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection
Michael Barry;Fiona Mulcahy;Concepta Merry;Sara Gibbons.
Clinical Pharmacokinectics (1999)
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations
Michael Barry;Sara Gibbons;David Back;Fiona Mulcahy.
Clinical Pharmacokinectics (1997)
St John's Wort increases expression of P-glycoprotein: Implications for drug interactions
Martina Hennessy;D Kelleher;J P Spiers;M Barry.
British Journal of Clinical Pharmacology (2002)
Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients.
Concepta Merry;Michael G. Barry;Fiona Mulcahy;Kathryn L. Halifax.
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.
L M Forrester;C J Henderson;M J Glancey;D J Back.
Biochemical Journal (1992)
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Sonia Rodríguez-Nóvoa;Pablo Labarga;Vincent Soriano;Deirdre Egan.
Clinical Infectious Diseases (2009)
Pharmacokinetic Drug Interactions with Oral Contraceptives
David J. Back;Michael LʼE. Orme.
Clinical Pharmacokinectics (1990)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: